101 related articles for article (PubMed ID: 23716272)
1. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
2. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Narayanan KR; Bansal D; Walia R; Sachdeva N; Bhansali A; Varma N; Marwaha RK
Pediatr Blood Cancer; 2013 Jul; 60(7):1148-53. PubMed ID: 23322583
[TBL] [Abstract][Full Text] [Related]
3. Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model.
Tauer JT; Ulmer A; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2014 May; 226(3):169-74. PubMed ID: 24819387
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
Shima H; Tokuyama M; Tanizawa A; Tono C; Hamamoto K; Muramatsu H; Watanabe A; Hotta N; Ito M; Kurosawa H; Kato K; Tsurusawa M; Horibe K; Shimada H
J Pediatr; 2011 Oct; 159(4):676-81. PubMed ID: 21592517
[TBL] [Abstract][Full Text] [Related]
7. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
9. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Millot F; Guilhot J; Baruchel A; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Nicolas Sirvent ; Yacouben K; Chastagner P; Gandemer V; Reguerre Y; Couillault G; Khalifeh T; Rialland F
Eur J Cancer; 2014 Dec; 50(18):3206-11. PubMed ID: 25459396
[TBL] [Abstract][Full Text] [Related]
10. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Hobernicht SL; Schweiger B; Zeitler P; Wang M; Hunger SP
Pediatr Blood Cancer; 2011 Apr; 56(4):671-3. PubMed ID: 21298759
[TBL] [Abstract][Full Text] [Related]
11. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Jönsson S; Standal T; Olsson B; Mellström D; Wadenvik H
Am J Hematol; 2012 May; 87(5):550-2. PubMed ID: 22407760
[TBL] [Abstract][Full Text] [Related]
12. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
13. Imatinib has adverse effect on growth in children with chronic myeloid leukemia.
Bansal D; Shava U; Varma N; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2012 Sep; 59(3):481-4. PubMed ID: 22052850
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
15. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
16. Does imatinib mesylate therapy cause growth hormone deficiency?
Kebapcilar L; Bilgir O; Alacacioglu I; Payzin B; Bilgir F; Oner P; Sari I; Calan M; Binicier O
Med Princ Pract; 2009; 18(5):360-3. PubMed ID: 19648757
[TBL] [Abstract][Full Text] [Related]
17. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
18. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Jiang Q; Jiang B; Chen SS; Jiang H; Qin YZ; Lai YY; Shi HX; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):6-9. PubMed ID: 22575184
[TBL] [Abstract][Full Text] [Related]
19. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
